<p>根据公司在最近向证券交易委员会提交的 13F 文件，Tredje AP fonden 在第四季度购买了 Jazz Pharmaceuticals PLC（纳斯达克代码：JAZZ - 免费报告）股票的新头寸。这家机构投资者购买了 43,200 股这家专业制药公司的股票，价值约为 7,344,000 美元。Tredje AP fonden 在最近一个季度末持有约 0.07% 的 Jazz Pharmaceuticals。</p>
<p>获取 <strong>Jazz Pharmaceuticals</strong> 警报：</p>
<ul>
<li>Zymeworks 为长期投资者提供希望</li>
</ul>
<p>其他几家大型投资者也增加或减少了对该公司的持股。Dimensional Fund Advisors LP 在第三季度将其在 Jazz Pharmaceuticals 的持股增加了 11.8%。Dimensional Fund Advisors LP 目前持有 2,836,652 股这家专业制药公司的股票，价值 373,855,000 美元，此前在上个季度又购买了 298,815 股。Capital World Investors 在第三季度将其在 Jazz Pharmaceuticals 的持股增加了 0.4%。Capital World Investors 目前持有 2,554,867 股这家专业制药公司的股票，价值 336,731,000 美元，此前在上个季度又购买了 10,345 股。Ameriprise Financial Inc. 在第二季度将其在 Jazz Pharmaceuticals 的持股增加了 11.4%。Ameriprise Financial Inc. 目前持有 1,867,399 股这家专业制药公司的股票，价值 198,159,000 美元，此前在上个季度又购买了 191,637 股。摩根大通在第三季度将其在 Jazz Pharmaceuticals 的持股增加了 8.5%。摩根大通目前持有 1,867,159 股这家专业制药公司的股票，价值 246,092,000 美元，此前在上个季度又购买了 145,865 股。最后，Vestal Point Capital LP 在第二季度以 127,344,000 美元的价格获得了 Jazz Pharmaceuticals 的新头寸。机构投资者和对冲基金持有该公司 89.14% 的股票。</p>
<h2>分析师升级和降级</h2>
<p>JAZZ 最近成为几份研究报告的主题。Raymond James Financial 在 5 月 6 日的报告中重申了对 Jazz Pharmaceuticals 的 &#34;跑赢大盘&#34; 评级，并设定了 239.00 美元的目标价。巴克莱在 5 月 6 日的报告中将 Jazz Pharmaceuticals 的目标价从 225.00 美元提高至 234.00 美元，并给予该股票 &#34;增持&#34; 评级。Leerink Partners 在 4 月 22 日的报告中将 Jazz Pharmaceuticals 的目标价从 215.00 美元提高至 225.00 美元，并给予该股票 &#34;跑赢大盘&#34; 评级。TD Cowen 在 5 月 6 日的研究报告中将 Jazz Pharmaceuticals 的目标价从 220.00 美元提高至 275.00 美元，并给予该公司 &#34;买入&#34; 评级。最后，加拿大皇家银行在 5 月 6 日的研究报告中将 Jazz Pharmaceuticals 的目标价从 195.00 美元提高至 258.00 美元，并给予该公司 &#34;跑赢大盘&#34; 评级。一位研究分析师对该股票给予了强烈买入评级，十五位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价为 238.00 美元。</p>
<ul>
<li>顶级大麻股票：投资机会丰富（你并没有错过机会）</li>
</ul>
<p><strong>阅读我们对 Jazz Pharmaceuticals 的最新分析</strong></p>
<h2>Jazz Pharmaceuticals 的内部交易</h2>
<p>在其他 Jazz Pharmaceuticals 的新闻中，首席会计官 Patricia Carr 于 3 月 9 日星期一出售了 1,287 股该股票。股票以平均价格 182.94 美元出售，总价值为 235,443.78 美元。出售完成后，首席会计官持有该公司 6,512 股，价值 1,191,305.28 美元。这笔交易代表了他们持股的 16.50% 的减少。该出售在与 SEC 的法律文件中披露，链接可通过此处获取。此外，执行副总裁 Neena M. Patil 于 2 月 26 日星期四出售了 55,600 股该股票。股票以平均价格 191.56 美元出售，总交易额为 10,650,736.00 美元。交易完成后，执行副总裁直接持有该公司 56,862 股，价值 10,892,484.72 美元。这笔交易代表了他们持股的 49.44% 的减少。该出售的披露在 SEC 文件中可获得。在上个季度，内部人士出售了价值 14,180,486 美元的 74,015 股公司股票。公司内部人士持有 4.30% 的股票。</p>
<h2>Jazz Pharmaceuticals 股票表现</h2>
<p>JAZZ 股票在星期三开盘价为 237.45 美元。该股票的市值为 149 亿美元，市盈率为 -11,866.57，市盈率/增长比率为 0.41，贝塔系数为 0.27。该公司的债务与股本比率为 0.95，流动比率为 2.04，速动比率为 1.85。该公司有 50 天的移动平均价格为 199.21 美元，200 天的移动平均价格为 178.13 美元。Jazz Pharmaceuticals PLC 的一年低点为 105.00 美元，一年高点为 238.55 美元。</p>
<p>Jazz Pharmaceuticals（纳斯达克代码：JAZZ - 获取免费报告）最后一次公布季度财报是在 3 月 31 日星期二。这家专业制药公司报告该季度每股收益为 6.34 美元。该公司在该季度的收入为 10.7 亿美元。Jazz Pharmaceuticals 的净利润率为 0.66%，股本回报率为 14.56%。作为一个整体，股票分析师预测 Jazz Pharmaceuticals PLC 在本年度将发布 20.75 美元的每股收益。</p>
<h2>Jazz Pharmaceuticals 简介</h2>
<p>（免费报告）</p>
<p>Jazz Pharmaceuticals plc 是一家全球生物制药公司，专注于开发和商业化神经科学和肿瘤学领域的疗法。该公司的研发工作针对睡眠障碍、血液恶性肿瘤、罕见神经疾病和实体肿瘤等未满足的医疗需求。Jazz 的产品组合包括治疗嗜睡症、肝静脉阻塞病、急性髓性白血病及其他严重疾病的疗法。</p>
<p>Jazz Pharmaceuticals 的旗舰产品包括 Xyrem®（氧丁酸钠）和 Xywav®（氧丁酸钙、镁、钾和钠），用于治疗嗜睡症患者的肌肉无力发作和白天过度嗜睡。</p>
<h2>另请参见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Jazz Pharmaceuticals</li>
<li>HIVE 利用电力进行 AI 转型</li>
<li>深入分析 NVIDIA 最新的投资组合动向</li>
<li>Brady Corp 启动了一次大规模的 AI 驱动突破</li>
<li>为什么 Home Depot 的抛售可能成为一个巨大的机会</li>
</ul>
<p><strong>想看看其他对 JAZZ 感兴趣的对冲基金持有什么吗？</strong> 请访问 HoldingsChannel.com，获取 Jazz Pharmaceuticals PLC（NASDAQ:JAZZ - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Jazz Pharmaceuticals 吗？</h2>
<p>在考虑 Jazz Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Jazz Pharmaceuticals 并不在名单上。</p>
<p>虽然 Jazz Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

爵士制药

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

医疗业 ETF - Vanguard

IBBQ

<p>根据最近的 SEC 文件，第三支柱养老金基金在第四季度收购了 43,200 股爵士制药（Jazz Pharmaceuticals PLC，NASDAQ:JAZZ），价值约 734 万美元。其他机构投资者也增加了他们的持股，维度基金顾问（Dimensional Fund Advisors）将持股提高了 11.8%。分析师对爵士制药给予了 “适度买入” 的评级，平均目标价格为 238.00 美元</p>

<p>Tredje AP fonden bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The institutional investor bought 43,200 shares of the specialty pharmaceutical company's stock, valued at approximately $7,344,000. Tredje AP fonden owned about 0.07% of Jazz Pharmaceuticals at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据公司在最近向证券交易委员会提交的 13F 文件，Tredje AP fonden 在第四季度购买了 Jazz Pharmaceuticals PLC（纳斯达克代码：JAZZ - 免费报告）股票的新头寸。这家机构投资者购买了 43,200 股这家专业制药公司的股票，价值约为 7,344,000 美元。Tredje AP fonden 在最近一个季度末持有约 0.07% 的 Jazz Pharmaceuticals。</p>
</div><p>Get <strong>Jazz Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Jazz Pharmaceuticals</strong> 警报：</p>
</div><ul>
<li>Zymeworks Offers Hope for More than Just Long-Term Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>Zymeworks 为长期投资者提供希望</li>
</ul>
</div><p>Several other large investors have also added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its holdings in Jazz Pharmaceuticals by 11.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company's stock worth $373,855,000 after purchasing an additional 298,815 shares during the last quarter. Capital World Investors boosted its holdings in Jazz Pharmaceuticals by 0.4% during the third quarter. Capital World Investors now owns 2,554,867 shares of the specialty pharmaceutical company's stock worth $336,731,000 after purchasing an additional 10,345 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company's stock worth $198,159,000 after purchasing an additional 191,637 shares during the last quarter. JPMorgan Chase &amp; Co. boosted its holdings in Jazz Pharmaceuticals by 8.5% during the third quarter. JPMorgan Chase &amp; Co. now owns 1,867,159 shares of the specialty pharmaceutical company's stock worth $246,092,000 after purchasing an additional 145,865 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new position in Jazz Pharmaceuticals during the second quarter worth $127,344,000. Institutional investors and hedge funds own 89.14% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者也增加或减少了对该公司的持股。Dimensional Fund Advisors LP 在第三季度将其在 Jazz Pharmaceuticals 的持股增加了 11.8%。Dimensional Fund Advisors LP 目前持有 2,836,652 股这家专业制药公司的股票，价值 373,855,000 美元，此前在上个季度又购买了 298,815 股。Capital World Investors 在第三季度将其在 Jazz Pharmaceuticals 的持股增加了 0.4%。Capital World Investors 目前持有 2,554,867 股这家专业制药公司的股票，价值 336,731,000 美元，此前在上个季度又购买了 10,345 股。Ameriprise Financial Inc. 在第二季度将其在 Jazz Pharmaceuticals 的持股增加了 11.4%。Ameriprise Financial Inc. 目前持有 1,867,399 股这家专业制药公司的股票，价值 198,159,000 美元，此前在上个季度又购买了 191,637 股。摩根大通在第三季度将其在 Jazz Pharmaceuticals 的持股增加了 8.5%。摩根大通目前持有 1,867,159 股这家专业制药公司的股票，价值 246,092,000 美元，此前在上个季度又购买了 145,865 股。最后，Vestal Point Capital LP 在第二季度以 127,344,000 美元的价格获得了 Jazz Pharmaceuticals 的新头寸。机构投资者和对冲基金持有该公司 89.14% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>JAZZ has been the subject of several recent research reports. Raymond James Financial restated an &#34;outperform&#34; rating and set a $239.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Barclays increased their target price on shares of Jazz Pharmaceuticals from $225.00 to $234.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, May 6th. Leerink Partners increased their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, April 22nd. TD Cowen increased their price target on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, May 6th. Finally, Royal Bank Of Canada increased their price target on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $238.00.</p>
<div class="lb-trans"><p>JAZZ 最近成为几份研究报告的主题。Raymond James Financial 在 5 月 6 日的报告中重申了对 Jazz Pharmaceuticals 的 &#34;跑赢大盘&#34; 评级，并设定了 239.00 美元的目标价。巴克莱在 5 月 6 日的报告中将 Jazz Pharmaceuticals 的目标价从 225.00 美元提高至 234.00 美元，并给予该股票 &#34;增持&#34; 评级。Leerink Partners 在 4 月 22 日的报告中将 Jazz Pharmaceuticals 的目标价从 215.00 美元提高至 225.00 美元，并给予该股票 &#34;跑赢大盘&#34; 评级。TD Cowen 在 5 月 6 日的研究报告中将 Jazz Pharmaceuticals 的目标价从 220.00 美元提高至 275.00 美元，并给予该公司 &#34;买入&#34; 评级。最后，加拿大皇家银行在 5 月 6 日的研究报告中将 Jazz Pharmaceuticals 的目标价从 195.00 美元提高至 258.00 美元，并给予该公司 &#34;跑赢大盘&#34; 评级。一位研究分析师对该股票给予了强烈买入评级，十五位分析师给予了买入评级，一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价为 238.00 美元。</p>
</div><ul>
<li>Top Marijuana Stocks: Plenty of Investment Opportunities Abound (You're not Late to the Game)</li>
</ul>
<div class="lb-trans"><ul>
<li>顶级大麻股票：投资机会丰富（你并没有错过机会）</li>
</ul>
</div><p><strong>Read Our Latest Analysis on Jazz Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Jazz Pharmaceuticals 的最新分析</strong></p>
</div><h2>Insider Transactions at Jazz Pharmaceuticals</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 的内部交易</h2>
</div><p>In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,287 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $182.94, for a total value of $235,443.78. Following the completion of the sale, the chief accounting officer owned 6,512 shares in the company, valued at $1,191,305.28. This trade represents a 16.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Neena M. Patil sold 55,600 shares of the stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the completion of the transaction, the executive vice president directly owned 56,862 shares in the company, valued at $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 74,015 shares of company stock valued at $14,180,486. 4.30% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Jazz Pharmaceuticals 的新闻中，首席会计官 Patricia Carr 于 3 月 9 日星期一出售了 1,287 股该股票。股票以平均价格 182.94 美元出售，总价值为 235,443.78 美元。出售完成后，首席会计官持有该公司 6,512 股，价值 1,191,305.28 美元。这笔交易代表了他们持股的 16.50% 的减少。该出售在与 SEC 的法律文件中披露，链接可通过此处获取。此外，执行副总裁 Neena M. Patil 于 2 月 26 日星期四出售了 55,600 股该股票。股票以平均价格 191.56 美元出售，总交易额为 10,650,736.00 美元。交易完成后，执行副总裁直接持有该公司 56,862 股，价值 10,892,484.72 美元。这笔交易代表了他们持股的 49.44% 的减少。该出售的披露在 SEC 文件中可获得。在上个季度，内部人士出售了价值 14,180,486 美元的 74,015 股公司股票。公司内部人士持有 4.30% 的股票。</p>
</div><h2>Jazz Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 股票表现</h2>
</div><p>Shares of JAZZ stock opened at $237.45 on Wednesday. The stock has a market cap of $14.90 billion, a P/E ratio of -11,866.57, a P/E/G ratio of 0.41 and a beta of 0.27. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The company has a fifty day moving average price of $199.21 and a two-hundred day moving average price of $178.13. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $238.55.</p>
<div class="lb-trans"><p>JAZZ 股票在星期三开盘价为 237.45 美元。该股票的市值为 149 亿美元，市盈率为 -11,866.57，市盈率/增长比率为 0.41，贝塔系数为 0.27。该公司的债务与股本比率为 0.95，流动比率为 2.04，速动比率为 1.85。该公司有 50 天的移动平均价格为 199.21 美元，200 天的移动平均价格为 178.13 美元。Jazz Pharmaceuticals PLC 的一年低点为 105.00 美元，一年高点为 238.55 美元。</p>
</div><p>Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. As a group, equities analysts predict that Jazz Pharmaceuticals PLC will post 20.75 EPS for the current year.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals（纳斯达克代码：JAZZ - 获取免费报告）最后一次公布季度财报是在 3 月 31 日星期二。这家专业制药公司报告该季度每股收益为 6.34 美元。该公司在该季度的收入为 10.7 亿美元。Jazz Pharmaceuticals 的净利润率为 0.66%，股本回报率为 14.56%。作为一个整体，股票分析师预测 Jazz Pharmaceuticals PLC 在本年度将发布 20.75 美元的每股收益。</p>
</div><h2>Jazz Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Jazz Pharmaceuticals 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals plc 是一家全球生物制药公司，专注于开发和商业化神经科学和肿瘤学领域的疗法。该公司的研发工作针对睡眠障碍、血液恶性肿瘤、罕见神经疾病和实体肿瘤等未满足的医疗需求。Jazz 的产品组合包括治疗嗜睡症、肝静脉阻塞病、急性髓性白血病及其他严重疾病的疗法。</p>
</div><p>Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals 的旗舰产品包括 Xyrem®（氧丁酸钠）和 Xywav®（氧丁酸钙、镁、钾和钠），用于治疗嗜睡症患者的肌肉无力发作和白天过度嗜睡。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than Jazz Pharmaceuticals</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Jazz Pharmaceuticals</li>
<li>HIVE 利用电力进行 AI 转型</li>
<li>深入分析 NVIDIA 最新的投资组合动向</li>
<li>Brady Corp 启动了一次大规模的 AI 驱动突破</li>
<li>为什么 Home Depot 的抛售可能成为一个巨大的机会</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JAZZ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 JAZZ 感兴趣的对冲基金持有什么吗？</strong> 请访问 HoldingsChannel.com，获取 Jazz Pharmaceuticals PLC（NASDAQ:JAZZ - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SkFaWg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=JAZZ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Jazz Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Jazz Pharmaceuticals 吗？</h2>
</div><p>Before you consider Jazz Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Jazz Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Jazz Pharmaceuticals 并不在名单上。</p>
</div><p>While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Jazz Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

43,200 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by Tredje AP fonden

Market Beat

Invesco Nasdaq Biotechnology ETF

Zymeworks

阿默普莱斯金融

摩根大通

瑞杰金融

巴克莱银行

Toronto Dominion Bank

加拿大皇家银行

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Tredje AP fonden 购入了爵士制药 PLC $JAZZ 的 43,200 股股票